Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
A TSPO ligand is protective in a mouse model of multiple sclerosis.
Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.
Electrophysiological features of POEMS syndrome and chronic inflammatory demyelinating polyneuropathy.
Diagnosis and classification of neuromyelitis optica (Devic's Syndrome).
Diagnosis and classification of autoimmune optic neuropathy.
Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program.
Multiple deep white matter lesions mimic multiple sclerosis as an unusual complication of left atrial myxoma.
Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
Myelin Basic Protein and a Multiple Sclerosis-related MBP-peptide Bind to Oligonucleotides.
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: Yes.
Balance.
Advanced MRI in multiple sclerosis: current status and future challenges.
Vitamin D and multiple sclerosis.
Gene Therapy of Multiple Sclerosis Using Interferon β -Secreting Human Bone Marrow Mesenchymal Stem Cells.
Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
[Pharmacological treatment of spasticity in multiple sclerosis].
ACTH gel in the treatment of multiple sclerosis exacerbation: a case study.
Stopping immunomodulatory medications in MS: Frequency, reasons and consequences.
HSP60 plays a regulatory role in IL-1β-induced microglial inflammation via TLR4-p38 MAPK axis.
Characterization of Axonal Disease in Patients with Multiple Sclerosis Using High-Gradient-Diffusion MR Imaging.
Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study.
Determining the Presence of Reliable Change over Time in Multiple Sclerosis: Evidence from the PASAT, Adjusting-PSAT, and Stroop Test.
Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple.
[A case of neuromyelitis optica presenting ileus as a neurologic finding].
Pages
« first
‹ previous
…
290
291
292
293
294
295
296
297
298
…
next ›
last »